Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker (dihydropyridine) presented as an intravenous formulation for use in acute care settings. It is employed to manage patients with subarachnoid hemorrhage and to help prevent cerebral vasospasm, thereby supporting cerebral blood flow and neuroprotection.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing consistent quality and regulatory compliance. The product meets EU pharmacopoeial standards and is manufactured under GMP conditions.

Nimotop (nimodipine) is used in the management of cerebrovascular conditions where cerebral vasospasm is a concern. - Subarachnoid hemorrhage: reduces the risk of delayed cerebral ischemia by mitigating vasospasm. - Prevention of cerebral vasospasm: maintains cerebral blood flow after aneurysmal bleed.

Nimotop may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Hypotension: transient drop in blood pressure, especially with rapid infusion. - Nausea: gastrointestinal upset that may resolve with continued use. - Flushing: warmth and redness of the skin. - Dizziness: sensation of light‑headedness, often related to blood pressure changes. - Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure decline requiring medical intervention. - Myocardial infarction: rare cardiac ischemic events. - Hepatic dysfunction: abnormal liver enzymes indicating liver stress. - Allergic reactions: rash, itching, or anaphylaxis in susceptible individuals. - Seizures: infrequent neurologic events. - Cardiac arrhythmias: abnormal heart rhythms beyond bradycardia.

Before initiating Nimotop, clinicians should assess patient-specific factors and monitor for potential complications. - Blood pressure monitoring: observe for hypotension during and after infusion. - Hepatic function: evaluate liver enzymes in patients with known liver disease. - Cardiac status: use cautiously in patients with existing cardiac conduction abnormalities. - Concomitant vasodilators: avoid simultaneous use with other potent vasodilators to prevent additive hypotension. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Nimotop can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nimodipine plasma levels and risk of toxicity. - Concurrent potent vasodilators (e.g., nitroglycerin): can cause severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal impairment. - Other antihypertensives: may augment blood‑pressure‑lowering effect. - Beta‑blockers: can mask compensatory tachycardia. - Diuretics: may exacerbate hypotensive episodes.